Sumitomo Pharma Co., Ltd.
Notice Regarding Recognition of Non-Operating Income in Our Standalone Financial Statements (Japanese GAAP)
In the standalone financial statements for the fiscal year ending March 2026, dividend income of JPY 48,340 million was recognized as non-operating income due to dividends paid by the consolidated subsidiary Sumitomo Pharma Switzerland GmbH.
Key Figures
- Dividend Income Received: JPY 48,340 million (Fiscal Year Ending March 2026, Standalone Financial Statements)
- Impact on Consolidated Earnings: None
- Period Covered: April 1, 2025 to March 31, 2026
AI要約
Details of Non-Operating Income
Sumitomo Pharma Co., Ltd. announced that in its standalone financial statements (Japanese GAAP) for the fiscal year ending March 2026 (April 1, 2025 to March 31, 2026), it recognized dividend income of JPY 48,340 million as non-operating income, resulting from dividends paid by its consolidated subsidiary Sumitomo Pharma Switzerland GmbH.
Impact on Financial Results
This dividend income is recorded in the standalone financial statements and is eliminated in the consolidated financial statements; therefore, it has no impact on consolidated earnings.
